June Supplement TOC
Agency Confidential: The Scoop- What Your Agency Doesn't Want To Tell You
I've Seen The Revolution and It's Not Working
Elaine EisenPRESIDENT | CORBETT WORLDWIDE HEALTHCARE COMMUNICATIONS
Ahnal PurohitPRESIDENT AND CEO | PUROHIT NAVIGATION
Al TopinPRESIDENT | TOPIN and ASSOCIATES
Jon HudsonVICE PRESIDENT OF MEDIA AND DIGITAL SERVICES | MEDTHINK COMMUNICATIONS
Geoff MelickEVP/INTERACTIVE MARKETING and EINNOVATION | KINECT INTERACTIVE DIGITAL COMMUNICATIONS
Carleen KellyPRESIDENT | SURGE WORLDWIDE HEALTHCARE COMMUNICATIONS
Ross FetterolfVP OF DIGITAL STRATEGY | IGNITE HEALTHPharmaceuticals
Jeff BurkelCMO | MICROMASS COMMUNICATIONS
Joe DaleyPRESIDENT | GSW WORLDWIDE/US OPERATIONS
Didi DiscarPARTNER | MEDACCESS
Frank X. PowersEXECUTIVE VICE PRESIDENT | DUDNYK
Donna WrayMANAGEMENT ADVISOR, LEADER OF INTERNET AND RELATIONSHIP MARKETING PRACTICE | TGAS ADVISORS
Jay CarterSENIOR VICE PRESIDENT, DIRECTOR OF CLIENT SERVICES | ABELSONTAYLOR
Wendy BlackburnEXECUTIVE VICE PRESIDENT | INTOUCH SOLUTIONS
Kerry HiltonPRESIDENT AND CEO | HC and B HEALTHCARE COMMUNICATIONS
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.